Abstract
There is a pressing need for comparative effectiveness research to improve mental health treatments. Although U.S. mental health spending has increased dramatically, mainly because of the rapid adoption of newer psychotropic medications, fewer than a quarter of people with serious mental illnesses receive appropriate care. Because of a general lack of information on the relative effectiveness of different treatments, payers are uncertain about the value of current spending, which in turn may deter new investments to reduce unmet need. We use several recent comparative effectiveness trials to illustrate the potential value of such research for improving practice and policy.
MeSH terms
-
Alzheimer Disease / drug therapy
-
Alzheimer Disease / economics
-
Antidepressive Agents / adverse effects
-
Antidepressive Agents / economics
-
Antidepressive Agents / therapeutic use
-
Antipsychotic Agents / adverse effects
-
Antipsychotic Agents / economics
-
Antipsychotic Agents / therapeutic use
-
Cost-Benefit Analysis
-
Depressive Disorder, Major / drug therapy
-
Depressive Disorder, Major / economics
-
Drug Costs / statistics & numerical data
-
Evidence-Based Medicine* / economics
-
Health Policy* / economics
-
Humans
-
Insurance Coverage
-
Insurance, Pharmaceutical Services
-
Mental Disorders / drug therapy*
-
Mental Disorders / economics
-
Psychotic Disorders / drug therapy
-
Psychotic Disorders / economics
-
Psychotropic Drugs / economics
-
Psychotropic Drugs / therapeutic use*
-
Randomized Controlled Trials as Topic*
-
Schizophrenia / drug therapy
-
Schizophrenia / economics
-
Treatment Outcome
-
United States
Substances
-
Antidepressive Agents
-
Antipsychotic Agents
-
Psychotropic Drugs